Humacyte (HUMA) Operating Expenses (2020 - 2026)

Humacyte (HUMA) has 7 years of Operating Expenses data on file, last reported at $29.4 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $29.4 million, up 24.17% year-over-year; the trailing twelve-month figure through Mar 2026 was $115.9 million (up 3.93% YoY), and the FY2025 annual result was $110.2 million, down 3.69% from the prior year.
• Operating Expenses declined to $29.4 million in Q1 2026 per HUMA's latest filing, from $31.3 million in the prior quarter.
• Over five years, Operating Expenses peaked at $31.3 million in Q4 2025 and troughed at $19.8 million in Q2 2022.
• A 5-year average of $25.9 million and a median of $26.2 million in 2023 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2023 and 2025: Operating Expenses soared 34.79% in 2023, then fell 16.84% in 2025.
• A 5-year view of Operating Expenses shows it stood at $20.8 million in 2022, then gained by 25.94% to $26.2 million in 2023, then advanced by 7.28% to $28.1 million in 2024, then advanced by 11.45% to $31.3 million in 2025, then retreated by 5.98% to $29.4 million in 2026.
• Business Quant data shows HUMA's Operating Expenses at $29.4 million in Q1 2026, $31.3 million in Q4 2025, and $25.1 million in Q3 2025.